Rovalpituzumab tesirine

Drug Profile

Rovalpituzumab tesirine

Alternative Names: Rova-T; SC16LD6.5

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Stemcentrx
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DLL3 protein inhibitors; DNA modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 27 Mar 2017 AbbVie, in collaboration with Stemcentrx, plans a phase I trial for Small cell lung cancer (Late-stage disease, Second-line therapy or greater, Recurrent) (NCT03086239)
  • 02 Mar 2017 AbbVie plans a phase III trial for Small cell lung cancer (Metastatic-disease, Late-stage disease, Second-line therapy or greater) (NCT03061812)
  • 07 Feb 2017 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03033511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top